Latest SLE Stories
-- CHABLIS-SC1 study passes futility analysis and will continue to completion with an enhanced endpoint HAYWARD, Calif., Feb.
A Substantial Need Remains for Emerging SLE Biologics That Can Prevent Acute Flares and That Treat Severe Manifestations, According to Findings from Decision Resources Group BURLINGTON, Mass.,
A new study reveals that one in six patients with systemic lupus erythematosus (SLE) is readmitted to the hospital within 30 days of being discharged.
--Novel Biologic Targets Innovative New Mechanism in Lupus-- SEATTLE, July 16, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of a multi-dose, one month
A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that, for the majority of lupus patients who are in remission, it is possible to successfully stop immunosuppressant therapy without triggering a flare of their disease.
SHENZHEN, China, May 13, 2014 /PRNewswire/ -- Chinese researchers have recently published new findings in Arthritis
- Significant clinical response to Acthar was observed in patients experiencing active disease while on conventional SLE maintenance therapies - ANAHEIM, Calif., May 5, 2014 /PRNewswire/ --
According to a new report from BCC Research, the global market for drugs to treat systemic lupus erythematosus (SLE), is expected to grow to $2.6 billion by 2018, with a five-year compound annual
--Novel Biologic Targets Innovative New Mechanism in Lupus-- SEATTLE, March 17, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of clinical studies with
- A serpent whose bite was fabled to produce intense thirst.